コンテンツへスキップ
Merck

Erythromycin: a motilin agonist and gastrointestinal prokinetic agent.

The American journal of gastroenterology (1993-04-01)
F H Weber, R D Richards, R W McCallum
要旨

Erythromycin, a commonly used antibiotic, has recently emerged as a potential gastrointestinal prokinetic agent. This follows a decade of research into the mechanism of well-recognized gastrointestinal side effects of erythromycin. Early investigations demonstrated that erythromycin increased gastrointestinal motility, and more recent studies suggest that it fortuitously binds to and stimulates the receptor for the gastrointestinal peptide motilin. From this work it appears that a new and powerful class of gastrointestinal prokinetic agents will evolve from erythromycin and its derivatives. The role of motilin in the genesis of the fasting and fed patterns of gastrointestinal motility is emerging through the study of these motilin agonists.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
エリスロマイシン, BioReagent, suitable for cell culture
Sigma-Aldrich
Erythromycin standard solution, 1 mg/mL in H2O
USP
エリスロマイシン, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
エリスロマイシン, potency: ≥850 μg per mg
Supelco
エリスロマイシン, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
エリスロマイシン, meets USP testing specifications
Sigma-Aldrich
エリスロマイシン, tested according to Ph. Eur.